| Entry |
| ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Name | Baloxavir marboxil (JAN/USAN/INN); Xofluza (TN) | ||||||||
| Product | XOFLUZA (A-S Medication Solutions), XOFLUZA (A-S Medication Solutions), XOFLUZA (Genentech) | ||||||||
| Formula | C27H23F2N3O7S | ||||||||
| Exact mass | 571.1225 | ||||||||
| Mol weight | 571.5492 | ||||||||
| Structure |  | ||||||||
| Simcomp | |||||||||
| Class | Antiviral DG03029 Anti-influenza virus agent | ||||||||
| Remark |
| ||||||||
| Efficacy | Antiviral, cap-dependent endonuclease inhibitor | ||||||||
| Disease | Influenza [DS:H00398] | ||||||||
| Comment | Antiviral for the treatment of influenza A and B Active form of prodrug: Baloxavir [DR:D11278] | ||||||||
| Target | Influenza A virus polymerase acidic protein [KO:K19390] | ||||||||
| Pathway |
| ||||||||
| Interaction | |||||||||
| Brite | Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] J ANTIINFECTIVES FOR SYSTEMIC USE J05 ANTIVIRALS FOR SYSTEMIC USE J05A DIRECT ACTING ANTIVIRALS J05AX Other antivirals J05AX25 Baloxavir marboxil D11021 Baloxavir marboxil (JAN/USAN/INN) <JP/US> USP drug classification [BR:br08302] Antivirals Anti-influenza Agents Baloxavir Marboxil D11021 Baloxavir marboxil (JAN/USAN/INN) Therapeutic category of drugs in Japan [BR:br08301] 6 Agents against pathologic organisms and parasites 62 Chemotherapeutics 625 Antivirals 6250 Antivirals D11021 Baloxavir marboxil (JAN/USAN/INN) Drug groups [BR:br08330] Antiviral DG03029 Anti-influenza virus agent DG02962 Baloxavir D11021 Baloxavir marboxil Drug classes [BR:br08332] Antiviral DG03029 Anti-influenza virus agent D11021 Baloxavir marboxil Antimicrobials [BR:br08307] Antivirals Genome replication inhibitor Other inhibitor D11021 Baloxavir marboxil (JAN/USAN/INN) <JP/US> New drug approvals in the USA [br08319.html] New molecular entities and new therapeutic biological products D11021 New drug approvals in Europe [br08329.html] European public assessment reports (EPAR) authorised medicine D11021 New drug approvals in Japan [br08318.html] Drugs with new active ingredients D11021 New drug approvals in the USA, Europe and Japan [br08328.html] Approval dates by FDA, EMA and PMDA D11021 Drug groups [BR:br08330] Antiviral DG03029 Anti-influenza virus agent DG02962 Baloxavir | ||||||||
| Other DBs |
| ||||||||
| KCF data | ATOM 40 1 N1y N 17.0975 -16.8144 2 N4y N 18.2887 -16.1138 3 C8y C 18.2887 -14.7124 4 C5x C 17.0975 -14.0117 5 N1y N 15.9064 -14.7124 6 C1y C 15.9064 -16.1138 7 C8x C 19.5499 -16.8144 8 C8x C 20.7410 -16.1138 9 C8y C 20.7410 -14.7124 10 C8y C 19.5499 -14.0117 11 C1x C 14.7152 -14.0117 12 C1x C 13.4540 -14.7124 13 O2x O 13.4540 -16.1138 14 C1x C 14.7152 -16.8144 15 O5x O 17.0975 -12.6104 16 O5x O 21.9322 -14.0117 17 O2a O 19.5499 -12.6104 18 C1b C 20.7410 -11.9097 19 O7a O 21.9322 -12.6104 20 C7a C 23.1233 -11.9097 21 O7a O 24.3145 -12.6104 22 C1a C 25.5056 -11.9097 23 O6a O 23.1233 -10.5084 24 C1x C 16.3969 -21.3688 25 C8y C 15.5560 -20.2477 26 C8y C 15.8363 -18.8464 27 C1y C 17.0975 -18.2858 28 S2x S 17.7982 -21.3688 29 C8y C 18.3587 -18.9164 30 C8y C 18.7091 -20.3178 31 C8x C 14.8554 -17.8654 32 C8x C 13.5241 -18.2858 33 C8y C 13.1738 -19.6171 34 C8y C 14.1547 -20.5981 35 C8x C 20.0404 -20.7382 36 C8x C 21.0914 -19.7573 37 C8x C 20.7410 -18.4260 38 C8x C 19.4098 -18.0056 39 X F 13.8044 -21.9293 40 X F 11.8425 -19.9675 BOND 45 1 1 2 1 2 2 3 1 3 3 4 1 4 4 5 1 5 5 6 1 6 1 6 1 7 2 7 1 8 7 8 2 9 8 9 1 10 9 10 1 11 3 10 2 12 5 11 1 13 11 12 1 14 12 13 1 15 13 14 1 16 6 14 1 17 4 15 2 18 9 16 2 19 10 17 1 20 17 18 1 21 18 19 1 22 19 20 1 23 20 21 1 24 21 22 1 25 20 23 2 26 26 27 1 27 24 28 1 28 27 29 1 29 25 26 1 30 28 30 1 31 24 25 1 32 29 30 1 33 26 31 2 34 31 32 1 35 32 33 2 36 33 34 1 37 25 34 2 38 30 35 2 39 35 36 1 40 36 37 2 41 37 38 1 42 29 38 2 43 34 39 1 44 33 40 1 45 27 1 1 #Down |